Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

NVIDIA debuts supercomputer for healthcare and AI research

By Brian Buntz | July 6, 2021

NVidiaSanta Clara, Calif.–based NVIDIA has launched the Cambridge-1, which it hails as “the United Kingdom’s most powerful supercomputer.”

Developed with healthcare applications in mind, NVIDIA invested some $100 million in the supercomputer.

Initial applications of the Cambridge-1 include using AI to improve drug development, explore the causes of dementia and identify genomic-based disease risk factors.

Early users of the Cambridge-1 include AstraZeneca (LON:AZN), GSK (NYSE:GSK), Oxford Nanopore, King’s College London, St. Thomas’ NHS Foundation Trust and Oxford Nanopore Technologies.

AstraZeneca’s focus of the computer will be on creating an open-source transformer-based generative AI model for chemical structures. The model can be used to predict chemical reactions, optimize molecules and generate de novo molecules.

AstraZeneca and NVIDIA are also teaming up to use Cambridge-1 to facilitate digital pathology to accelerate the process of annotating whole slide tissue sample images.

Cambridge-1 supercomputer from NVIDIA

Cambridge-1 supercomputer from NVIDIA

GSK plans to use the computer to genetically validate targets for drug development. GSK has already made significant investments in AI and genomics. The company expects Cambridge-1 to add additional computational horsepower to its drug discovery efforts.

Cambridge-1 uses NVIDIA’s DGX A100 SuperPOD technology, which is also present in the company’s Selene supercomputer, which the Top 500 rankings of supercomputers ranked as the sixth fastest.

The Cambridge-1 draws its power from entirely renewable sources.

“The discoveries developed on Cambridge-1 will take shape in the U.K., but the impact will be global, driving groundbreaking research that has the potential to benefit millions around the world,” said NVIDIA CEO Jensen Huang in a statement.


Filed Under: Drug Discovery, Drug Discovery and Development
Tagged With: AstraZeneca, AstraZeneca plc, Cambridge-1, DGX A100 SuperPOD, digital pathology, GlaxoSmithKline, GSK, NVIDIA, supercomputer
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Black Diamond Therapeutics
Black Diamond analysis highlights 22 new oncogenic HER2 driver mutations
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50